Argos Therapeutics

Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company is pioneering the development of individualized immunotherapy, using its combined mRNA and dendritic cell technology to deliver specifically targeted treatments, one patient at a time. Using material from both disease and blood samples collected from each patient, its Arcelis-based immunotherapies arm the patient’s dendritic cells to trigger a targeted patient-specific immune response.

Company Growth (employees)
Type
Public
HQ
Durham, US
Founded
1997
Size (employees)
122 (est)-10%
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr

Argos Therapeutics Data and Metrics

Argos Therapeutics Financial Metrics

Argos Therapeutics's revenue was reported to be $105.3 k in Q1, 2017
USD

Revenue (Q1, 2017)

105.3 k

Net income (Q1, 2017)

(24.1 m)

EBIT (Q1, 2017)

(44 m)

Market capitalization (17-Aug-2017)

8.2 m
Argos Therapeutics's current market capitalization is $8.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

2 m518.3 k945.5 k

Revenue growth, %

(74%)82%

R&D expense

45.5 m62.1 m38.3 m

General and administrative expense

8.6 m11 m14.2 m

Operating expense total

54.1 m73.1 m53.3 m

EBIT

(52.1 m)(72.5 m)(52.3 m)

EBIT margin, %

(2641%)(13996%)(5532%)

Interest expense

(1.1 m)(2.3 m)(1.8 m)

Interest income

66.6 k25.4 k57.3 k

Net Income

(53.3 m)(74.8 m)(53 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

473.2 k398.6 k178.8 k107.4 k158.3 k146.4 k488.6 k146.8 k105.3 k

R&D expense

10.6 m13 m14.8 m16.1 m17.2 m9.5 m9.2 m9.3 m7.9 m

General and administrative expense

1.9 m2.3 m2.4 m2.9 m2.7 m3 m3.4 m3 m4 m

Operating expense total

12.4 m15.3 m17.1 m19 m19.9 m12.5 m12.6 m12.4 m11.9 m

EBIT

(12 m)(14.9 m)(17 m)(18.9 m)(19.8 m)(12.3 m)(12.1 m)(12.2 m)(44 m)

EBIT margin, %

(2528%)(3743%)(9487%)(17587%)(12478%)(8421%)(2469%)(8316%)(41787%)

Interest expense

(171.6 k)(179.8 k)(594.9 k)(725.5 k)(324.9 k)(491.2 k)(543.5 k)(448.3 k)(728.4 k)

Interest income

21.3 k14.3 k10.1 k8.3 k4.8 k1.6 k2.2 k20.6 k30.6 k

Net Income

(12 m)(15.1 m)(17.5 m)(19.6 m)(20.1 m)(12.8 m)(12.6 m)(12.2 m)(24.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

37.2 m6.2 m53 m

Accounts Receivable

129 k73.8 k136.1 k

Current Assets

57.5 m8.8 m55.5 m

PP&E

5.5 m22.3 m41 m

Total Assets

64.4 m31.1 m97.2 m

Accounts Payable

1.9 m2.9 m5.4 m

Total Debt

122.9 k

Current Liabilities

3.3 m8.2 m30.6 m

Additional Paid-in Capital

235.6 m250.9 m338.2 m

Retained Earnings

(204.2 m)(279 m)(332 m)

Total Equity

(28.2 m)

Debt to Assets Ratio

0 x

Financial Leverage

-1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

44.3 m50.3 m29 m23 m20 m13.8 m34.8 m69.3 m

Accounts Receivable

265.5 k163.2 k163.7 k57 k130.8 k91.4 k461.1 k119.3 k137.2 k

Current Assets

72.9 m70.9 m40.4 m33 m24.9 m15.5 m37.3 m71.3 m25.5 m

PP&E

1.8 m4.5 m11.2 m15.5 m19 m27.3 m29.1 m37.5 m4.3 m

Total Assets

74.7 m76.8 m53.3 m49 m44.3 m42.8 m66.4 m108.8 m29.8 m

Accounts Payable

2.2 m3.1 m3.6 m4.7 m3.1 m6.2 m5.1 m3.6 m3.4 m

Current Liabilities

3.8 m4.9 m5.6 m7.5 m8.4 m14.6 m17.9 m23.9 m17.1 m

Additional Paid-in Capital

233.5 m234.7 m236.7 m246.2 m247.6 m271.7 m308.7 m336.9 m342.4 m

Retained Earnings

(172.8 m)(187.9 m)(221.7 m)(241.3 m)(261.4 m)(291.8 m)(304.4 m)(316.6 m)(356.1 m)

Total Equity

4.7 m(13.9 m)

Financial Leverage

10.4 x-3.2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(53.3 m)(74.8 m)(53 m)

Depreciation and Amortization

566.1 k680.4 k952.3 k

Accounts Receivable

(252 k)(629 k)(906 k)

Accounts Payable

543.4 k(137 k)1.2 m

Cash From Operating Activities

3.9 m(31.1 m)(40.7 m)

Purchases of PP&E

(1.1 m)(9.7 m)(15.3 m)

Cash From Investing Activities

(7.8 m)8.9 m(14.3 m)

Long-term Borrowings

(51.5 k)(35.5 k)(1.6 m)

Cash From Financing Activities

57 m21.1 m101.8 m

Interest Paid

307.9 k1.6 m2.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12 m)(15.1 m)(17.5 m)(19.6 m)(20.1 m)(12.8 m)(12.6 m)(12.2 m)(24.1 m)

Accounts Receivable

265.5 k163.2 k163.7 k57 k130.8 k91.4 k461.1 k119.3 k137.2 k

Accounts Payable

2.2 m3.1 m3.6 m4.7 m3.1 m6.2 m5.1 m3.6 m3.4 m
USDY, 2017

Revenue/Employee

816

Argos Therapeutics Market Value History

Traffic Overview of Argos Therapeutics

Argos Therapeutics Online and Social Media Presence

Argos Therapeutics Company Life and Culture

You may also be interested in